Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer

British Journal of Cancer

Volumn 82, Issue 3, 2000, Pages 501-513

  Nicholson, R I ^a   Gee, J M W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

BREAST CANCER; CELL CYCLE; CELL PROLIFERATION; HORMONE RESISTANCE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033973395     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0954     Document Type: Review

References (224)

1. Ali S, Metzger D, Bornert JM and Chambon P (1993) Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 12: 1153-1160
2. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP and Kraus MH (1995) Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821
3. Amoils KD and Bezwoda WR (1997) TGF-beta 1 mRNA expression in clinical breast cancer and its relationship to ER mRNA expression. Breast Cancer Res Treat 42: 95-101
4. Amundadottir LT, Nass SJ, Berchem GJ, Johnson MD and Dickson RB (1996) Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene 13: 757-765
5. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and Meltzer PS (1997) AIBI, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968
6. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI and Robertson JFR (1995) Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259-1266
7. Arnold SF, Obourn JD, Jaffe H and Notides AC (1994) Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 8: 1208-1214
8. Arnold SF, Melamed M, Vorojeikina DP, Notides AC and Sasson S (1997) Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol Endocrinol 11: 48-53
9. Aronica SM and Katzenellenbogen BS (1993) Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7: 743-752
10. Arteaga CL and Osborne CK (1989) Growth inhibition of human breast cancer cells in vitro with an antibody against the type 1 somatomedin receptor. Cancer Res 49(22): 6237-6241
11. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD and Pietenpol JA (1993) Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 4: 193-201
12. Arteaga CL, Koli KM, Dugger TC and Clarke R (1999) Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 91: 46-53
13. Astrue ME, Chabret C, Bali P, Gagne D and Pons M (1995) Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology 136: 824-832
14. Badia E, Duchesne MJ, Astrue M, Fuentes M, Gagne D, Nicolas JC, Pons M (1995) Modulation of cellular response expression during prolonged treatment with antiestrogens. C R Seances Soc Biol Fil 189: 755-764
15. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME and Salomon DS (1988) Expression of transforming growth factor-alpha and its mRNA in human breast cancer: its regulation by oestrogen and its possible functional significance. Mol Endocrinol 2: 543-555
16. Benz CC, O'Hagan Re, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A and Hassell JA (1997) HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15: 1513-1525
17. Berns EM, van Staveren IL, Klijn JG and Foekens JA (1998) Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat 48: 87-92
18. Berthois Y, Dong XF and Martin PM (1989) Regulation of epidermal growth factor receptor by oestrogen and antioestrogen in the human breast cancer cell line MCF-7. Biochem Biophys Res Commun 159: 126-131
19. Bland KI, Konstadoulakis MM, Vezeridis MP and Wanebo HJ (1995) Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221: 706-718
20. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW and Nicholson RI (1989) Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943-947
21. Brunner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME and Cullen KJ (1993) Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur J Cancer 29: 562-569
22. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA and Sutherland RL (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133
23. Bunone G, Briand PA, Miksicek RJ and Picard D (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15: 2174-2183
24. Callans LS, Naama H, Khandelwal M, Plotkin R and Jardines L (1995) Raf-1 protein expression in human breast cancer cells. Ann Surg Oncol 2: 38-42
25. Campbell FC, Blamey RW, Elston CW, Morris AH, Nicholson RI, Griffiths K and Haybittle JL (1981) Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 2: 1317-1319
26. Casalini P, Menard S, Malandrin SM, Rigo CM, Colnaghi MI, Cultraro CM and Segal S (1997) Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. Int J Cancer 72: 631-636
27. Castronovo V, Taraboletti G, Liotta LA and Sobel ME (1989) Modulation of laminin receptor expression by estrogen and progestins in human breast cancer cell lines. J Natl Cancer Inst 81: 781-788
28. Cheung KL, Willsher PC, Pinder SE, Ellis IO, Elston CW, Nicholson RI, Blamey RW and Robertson JF (1997) Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat 45: 219-224
29. Cho H and Katzenellenbogen BS (1903) Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Mol Endocrinol 7: 441-452
30. Cho H, Aronica SM and Katzenellenbogen BS (1994) Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology 134: 658-664
31. Ciardiello F, Kim N, McGeady ML, Liscia DS, Saeki T, Bianco C and Salomon DS. Expression of transforming growth factor alpha in breast cancer. Ann Oncol 2: 169-182
32. Daffada AA, Johnston SR, Smith IE, Detre S, King N and Dowsett M (1995) Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 55: 288-293
33. Dalal BI, Keown PA and Greenberg AH (1993) Immunocytochemical localisation of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143: 381-389
34. Daly RJ, Binder MD and Sutherland RL (1994) Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 9: 2723-2727
35. Daly RJ, Carrick N and Darbre PD (1995) Progression to steroid autonomy is accompanied by altered sensitivity to growth factors in S115 mouse mammary tumour cells. J Steroid Biochem Mol Biol 54: 21-29
36. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G and De Bortoli M (1991) c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47: 833-838
37. Davis RJ (1995) Transcriptional regulation by MAP kinases. Mol Reprod Dev 42: 459-467
38. deConinck EC, McPherson LA and Weigel RJ (1995) Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol 15: 2191-2196
39. Dejardin E, Bonizzi G, Bellahcene A, Castronovo V, Merville MP and Bours V (1995) Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11: 1835-1841
40. DePasquale JA (1998) Cell matrix adhesions and localization of the vitronectin receptor in MCF-7 human mammary carcinoma cells. Histochem Cell Biol 110: 485-494
41. Diamond MI, Miner JN, Yoshinaga SK and Yamamoto KR (1990) Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249: 1266-1272
42. Dorssers LC and van Agthoven T (1996) Genetic mechanisms of estrogen-inependence in breast cancer. Pathol Res Pract 192: 743-751
43. Dotzlaw H, Leygue E, Watson PH and Murphy LC (1997) Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 82: 2371-2374
44. Dowsett M (1996) Endocrine resistance in advanced breast cancer. Acta Oncol 35: 91-95
45. Dowsett M, Daffada A, Chan CM and Johnston SR (1997) Oestrogen receptor mutants and variants in breast cancer. Eur J Cancer 33: 1177-1183
46. Duan R, Porter W and Safe S (1998) Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139: 1981-1990
47. Dubik D and Shiu RP (1992) Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7: 1587-1594
48. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA and Cross-Doersen DE (1996) Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7: 351-359
49. El-Ashry D, Miller DL, Kharbanda S, Lippman ME and Kern FG (1997) Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15: 423-435
50. El-Tanani MK and Green CD (1997) Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 60: 269-276
51. Falette NS, Fuqua SA, Chamness GC, Cheah MS, Greene GL and McGuire WL (1990) Estrogen receptor gene methylation in human breast tumors. Cancer Res 50: 3974-3978
52. Ferguson AT and Davidson NE (1997) Regulation of estrogen receptor alpha function in breast cancer. Crit Rev Oncog 8: 29-46
53. Ferguson AT, Lapidus RG and Davidson NE (1998) The regulation of estrogen receptor expression and function in human breast cancer. In: Biological and Hormonal Therapies of Cancer, Foon KA and Muss HB (eds). Kluwer Academic Publishers: Boston
54. Flynn A and Proud G (1996) Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway. FEBS Lett 389: 162-166
55. Freiss G, Prebois C, Rochefort H and Vignon F (1990) Anti-steroidal and anti-growth factor activities of anti-oestrogens. J Steroid Biochem Mol Biol 37: 777-781
56. Freiss G and Vignon F (1994) Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol Endocrinol 8: 1389-1396
57. Freiss G, Puech C and Vignon F (1998) Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. Mol Endocrinol 12: 568-579
58. Gangolli EA, Conneely OM and O'Malley BW (1997) Neurotransmitters activate the human estrogen receptor in a neuroblastoma cell line. J Steroid Biochem Mol Biol 61: 1-9
59. Gee, JMW, Ellis IO, Robertson JFR, Willsher P, McClelland RA, Hewitt KN, Blamey RW and Nicholson RI (1995) Immunocytochemical localization of FOS protein in human breast cancers and its relationship to a series of prognostic markers & response to endocrine therapy. Int J Cancer (Pred Oncol) 64: 269-273
60. Gee JWM, McClelland RA and Nicholson RI (1996) Growth factors and endocrine sensitivity in breast cancer. In: Molecular and Clinical Endocrinology. Pasqualini JR and Katzenellenbogen BS (eds). pp. 169-197. Marcel Dekker
61. Gee, JMW, Willsher P, Kenny FS, Robertson JFR, Pinder SE, Ellis IO and Nicholson RI (1999) Endocrine response and resistance in breast cancer: a role for the transcription factor FOS. Int J Cancer (Pred Oncol) 84: 54-61
62. Giani C, Pinchera A, Rasmussen A, Fierabracci P, Bonacci R, Campini D, Bevilacqua G, Trock B, Lippman ME and Cullen KJ (1998) Stromal IGF-II messenger RNA in breast cancer: relationship with progesterone receptor expressed by malignant epithelial cells. J Endocrinol Invest 21: 160-165
63. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH and Shaw PE (1995) ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 14: 951-962
64. Gorsch SM, Memoli VA, Stukel TA, Gold LI and Arrick BA (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52: 6949-6952
65. Gordge PC, Hulme MJ, Clegg RA and Miller WR (1996) Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer 32A: 2120-2126
66. Gudas JM, Klein RC, Oka M and Cowan KH (1995) Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. Clin Cancer Res 1: 235-243
67. Guerin M, Sheng ZM, Andrieu N and Riou G (1990) Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 5: 131-135
68. Gupta S and Davis RJ (1994) MAP kinase binds to the NH2-terminal activation domain of C-Myc. FEBS Lett 353: 281-285
69. Guvakova MA and Surmacz E (1997) Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57: 2606-2610
70. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R and Brown M (1996) p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 93: 11540-11545
71. Herman ME and Katzenellenbogen BS (1994) Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867-5874
72. Hill CS (1996) Signalling to the nucleus by members of the transforming growth factor-beta (TGF-beta) superfamily. Cell Signal 8: 533-544
73. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A and Bhalla K (1997) Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42: 73-81
74. Hui R, Cornish AL, McClelland RA, Robertson JFR, Blamey RW, Musgrove EA, Nicholson RI and Sutherland RL (1996) Cyclin DI and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 2: 923-928
75. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA and Korach KS (1996) Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137: 1735-1744
76. Janes PW, Daly RJ, deFazio A and Sutherland RL (1994) Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9: 3601-3608
77. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J and Lannigan DA (1998) pp90rsk 1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18: 1978-1984
78. Jones RM, Branda J, Johnston KA, Polymenis M, Gadd M, Rustgi A, Callanan L. and Schmidt EV (1996) An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 16: 4754-4764
79. Karnik PS, Kulkarni S, Liu XP, Budd GT and Bukowski RM (1994) Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54: 349-353
80. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E and Kawashima H (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494
81. Kerekatte V, Smiley K, Hu B, Smith A, Gelder F and De Benedetti A (1995) The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 64: 27-31
82. Klijn JG, Berns PM, Schmitz PI and Foekens JA (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Res 13: 3-17
83. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R and Dickson RB (1987) Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428
84. Knabbe C, Kopp A, Hilgers W, Lang D, Muller V, Zugmaier G and Jonat W (1996) Regulation and role of TGF beta production in breast cancer. Ann NY Acad Sci 784: 263-276
85. Knowlden JM, Gee JM, Seery LT, Farrow L, Gullick WJ, Ellis IO, Blamey RW, Robertson JF and Nicholson RI (1998) c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17: 1949-1957
86. Kreipe H, Feist H, Fischer L, Felgner J, Heidorn K, Mettler L and Parwaresch R (1993) Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53: 1956-1961
87. Kyprianou N, English HF, Davidson NE and Isaacs JT (1991) Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162-166
88. Lahooti H, Thorsen T and Aakvaag A (1998) Modulation of mouse estrogen receptor transcription activity by protein kinase C delta. J Mol Endocrinol 20: 245-259
89. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JPJ and Davidson NE (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2: 805-810
90. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG and Rose DW (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-2925
91. Lavoie JN, Rivard N, L'Allemain G and Pouyssegur J (1996) A temporal and biochemical link between growth factor-activated MAP kinases, cyclin DI induction and cell cycle entry. Prog Cell Cycle Res 2: 49-58
92. Le Goff P, Montano MM, Schodin DJ and Katzenellenbogen BS (1994) Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269: 4458-4466
93. Lee AV, Weng CN, Jackson JG and Yee D (1997) Activation of estrogen receptor-mediated gene transcription by 1GF-I in human breast cancer cells. J Endocrinol 152: 39-47
94. Lehrer S, O'Shaughnessy J, Song HK, Levine E, Savoretti P, Dalton J, Lipsztein R, Kalnicki S and Bloomer WD (1989) Activity of pp60c-src protein kinase in human breast cancer. Mt Sinai J Med 56: 83-85
95. Lewis TS, Shapiro PS and Ahn NG (1998) Signal tranduction through MAP kinase cascades. Adv Cancer Res 74: 49-139
96. Leygue E, Dotzlaw H, Watson PH and Murphy LC (1998) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 58: 3197-3201
97. Li BD, Liu L, Dawson M and De Benedetti A (1997) Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79: 2385-2390
98. Li BD, McDonald JC, Nassar R and De Benedetti A (1998) Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 227: 756-761; discussion 761-763
99. Linardopoulos S, Malliri A, Pintzas A, Vassilaros S, Tsikkinis A and Spandidos DA (1990) Elevated expression of AP-1 activity in human breast tumors as compared to normal adjacent tissue. Anticancer Res 10: 1711-1713
100. Locker AP, Birrell K, Bell JA, Nicholson RI, Elston CW, Blamey RW and Ellis IO (1992) Ki-67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol 18: 224-229
101. Lu B, Leygue E, Dotzlaw H, Murphy LJ, Murphy LC and Watson PH (1998) Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol 138: 199-203
102. Lukas J, Bartkova J and Bartek J (1996) Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled GI checkpoint. Mol Cell Biol 16: 6917-6925
103. Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S and Sorvillo JM (1991) Expression of neu protein, EGFR, and transforming growth factor alpha in breast cancer: correlation with clinicopathological parameters. Am J Pathol 138: 1527-1534
104. Lupu R, Cardillo M, Harris L, Hijazi M and Rosenberg K (1995) Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol 6: 135-145
105. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D and Tang C (1996) The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38: 57-66
106. MacCallum J, Bartlett JM, Thompson AM, Keen JC, Dixon JM and Miller WR (1994) Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer 69: 1006-1009
107. MacCallum J, Keen JC, Bartlett JM, Thompson AM, Dixon JM and Miller WR (1996) Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. Br J Cancer 74: 474-478
108. Maemura M, Akiyama SK, Woods VI, Jr and Dickson RB (1995) Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells. Clin Exp Metastas 13: 223-235
109. Manning DL, McClelland RA, Gee JM, Chan CM, Green CD, Blamey RW and Nicholson RI (1993) The role of four oestrogen-responsive genes, pL1V1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur J Cancer 29A: 1462-1468
110. Manning DL, McClelland RA, Knowlden JM, Bryant S, Gee JMW, Gree CD, Robertson JFR, Blamey RW, Sutherland RL, Ormandy CJ and Nicholson RI (1995) Differential expression of oestrogen regulated genes in breast cancer. Acta Oncol 34: 641-646
111. Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA and Iglehart JD (1997) BRCA1 expression is not directly responsive to estrogen. Oncogene 14: 115-121
112. Matsuda S, Kadowaki Y, Ichino M, Akiyama T, Toyoshima K and Yamamoto T (1993) 17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc Natl Acad Sci USA 90: 10803-10807
113. Matsui Y, Halter SA, Holt JT, Hogan BL and Coffey RJ (1990) Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61: 1147-1155
114. McClelland RA, Gee JMW, O'Sullivan L, Barnes DM, Robertson JFR, Ellis IO and Nicholson RI (1999) p21WAF1 expression and endocrine response in breast cancer. J Pathol (in press)
115. McDonnell DP, Vegeto E and O'Malley BW (1992) Identification of a negative regulatory function for steroid receptors. Proc Natl Acad Sci USA 89: 10563-10567
116. McDonnell DP, Dana SL, Hoener PA, Lieberman BA, Imhof MO and Stein RB (1995) Cellular mechanisms which distinguish between hormone-and antihormone-activated estrogen receptor. Ann N Y Acad Sci 761: 121-137
117. McInerney EM, Weis KE, Sun J, Mosselman S and Katzenellenbogen BS (1998) Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 139: 4513-4522
118. Merkel DE and Osborne CK (1989) Prognostic factors in breast cancer. Hematol Oncol Clin North Am 3: 641-652
119. Migliaccio A, Pagano M and Auricchio F (1993) Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 8: 2183-2191
120. Millon R, Nicora F, Muller D, Eber M, Klein-Soyer C and Abecassis J (1989) Modulation of human breast cancer cell adhesion by estrogens and antiestrogens. Clin Exp Metastas 7: 405-415
121. Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R and Karin M (1994) c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell Biol 14: 6683-6688
122. Mohamood AS, Gyles P, Balan KV, Hollis VW, Eckberg WR, Asseffa A, Han Z, Wyche JH and Anderson WA (1997) Estrogen receptor, growth factor receptor and protooncogene protein activities and possible signal transduction crosstalk in estrogen dependent and independent breast cancer cell lines. J Submicrose Cytol Pathol 29: 1-17.
123. Morishita S, Niwa K, Ichigo S, Hori M, Murase T, Fujimoto J and Tamaya T (1995) Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogens. Cancer Lett 97: 225-231
124. Murphy LC, Dotzlaw H, Leygue E, Douglas D, Coutts A and Watson PH (1997) Estrogen receptor variants and mutations. J Steroid Biochem Mol Biol 62: 363-372
125. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK and Sutherland RI, (1993) Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13: 3577-3587
126. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639
127. Nass SJ, Li M, Amundadottir LT, Furth PA and Dickson RB (1996) Role for Bcl-xl, in the regulation of apoptosis by EGF and TGF beta 1 in c-myc overexpressing mammary epithelial cells. Biochem Biophys Res Commun 227: 248-256
128. Nass SJ and Dickson RB (1998) Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc. Clin Cancer Res 4: 1813-1822
129. Nicholson RI, Wilson DW, Richards G, Griffiths K, Williams M, Elston CW and Blamey RW (1984) Biological and clinical aspects of oestrogen receptor measurements in rapidly progressing breast cancer. In: Proc. IUPHAR 9th International Congress of Pharmacology, Vol 3. Paton W, Mitchell J and Turner P (eds), pp. 75-79. McMillan Press: London
130. Nicholson RI, Colin P, Francis AB, Keshra R, Finlay P, Williams M, Elston CW, Blamey RW and Griffiths K (1986) Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers. Cancer Res 46: 4299s-4302s
131. Nicholson RI, Eaton CL and Manning DL (199?) New developments in the endocrine management of breast cancer. In: Recent Advances in Endocrinology and Metabolism, Vol 4, Edwards CRW and Lincoln DW (eds). pp. 151-165. Churchill Livingstone: Edinburgh
132. Nicholson RI, Bouzubar N, Walker KJ, McClelland R, Dixon AR, Robertson JF, Ellis IO and Blamey RW (1991) Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 27: 908-913
133. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JFR, Ellis IO and Blamey RW (1993) Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018-1023
134. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO and Blamey RW (1994) Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Res 54: 1684-1689
135. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JFR, Ellis IO and Blamey RW (1994) Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29: 117-125
136. Nicholson RI, McClelland RA and Gee JM (1995) Steroid hormone receptors and their clinical significance in cancer. J Clin Pathol 48: 890-895
137. Nicholson RI and Gee JWM (1996) Growth factors and modulation of endocrine response in breast cancer. In: Hormones and Cancer, Vedeckis WV (ed), pp. 227-261. Birkhauser: Boston
138. Nicholson RI, Gee JMW, Harper ME, Ellis IO, Willsher P and Robertson JFR (1997a) erbB signalling in clinical breast cancer: relationship to endocrine sensitivity. Endocrine-Related Cancer 4: 297-306
139. Nicholson RI, Gee JMW, Jones H, Harper ME, Wakeling AE, Willsher P and Robertson JFR (1997b) erbB signalling and endocrine sensitivity of human breast cancer. In: EGF Receptor in Tumour Growth and Progression, Harkin et al (eds) pp. 105-128 Springer Verlag: Bosten
140. Nicholson RI, Gee JMW, Seery LT, McClelland RA, Harper ME, Holt B, Barnes D, Robert son JFR, Pinder S and Ellis IO (1997c) p53 protein expression in human breast cancer: Relationship to tumour differentiation and endocrine response. ESO - Special Scientific Reports
141. Nicholson RI, Robertson JFR, Seery LT and Gee JMW (1999a) Endocrine response and failure in breast cancer: a role for the interplay of steroid and growth factor signalling pathways and therapeutic implications. In: Furr BJA and Jordan, VC (eds) Pharmacological Handbook (in press)
142. Nicholson RI, McClelland RA, Robertson JFR and Gee JMW (1999b) Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocrine-Related Cancer (in press)
143. Nicholson S, Halcrow P, Fardon JR, Sainsbury JRC, Chambers P and Harris AL (1989) Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet I 182-185
144. Osin P, Gusterson BA, Philp E, Waller J, Bartek J, Peto J and Crook T (1998) Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 34: 1683-1686
145. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB and Davidson NE (1994) Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54: 2552-2555
146. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ and Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510
147. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID and Pezzino V (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53: 3736-3740
148. Parker MG (1998) Transcriplional activation by oestrogen receptors. Biochem Soc Symp 63: 45-50
149. Paul A, Wilson S, Belham CM, Robinson CJ, Scott PH, Gould GW and Plevin R (1997) Stress-activated protein kinases: activation, regulation and function. Cell Signal 9: 403-410
150. Perry RR, Kang Y and Greaves BR (1995) Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441-1446
151. Pfahl M (1993) Nuclear receptor/AP-1 interaction. Endocr Rev 14: 651-658. of c-Myc. FEBS Lett 353(3): 281-5
152. Pfahl M (1993) Nuclear receptor/AP-1 interaction. Endocr Rev 14: 651-658. of c-Myc. FEBS Lett 353(3): 281-5
153. Philips A, Chalbos D and Rochefort H (1993) Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268: 14103-14108
154. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX and Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446
155. Porter W, Saville B, Hoivik D and Safe S (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11: 1569-1580
156. Prall OW, Rogan EM and Sutherland RL (1998a) Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol 65: 169-174
157. Prall OW, Rogan EM, Musgrove EA, Watts CK and Sutherland RL (1998b) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18: 4499-4508
158. Ram TG, Kokeny KE, Dilts CA and Ethier SP (1995) Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells. J Cell Physiol 163: 589-596
159. Ray P, Ghosh SK, Zhang DH and Ray A (1997) Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-1L6 and NF-kappa B by the estrogen receptor. FEBS Lett 409: 79-85
160. Reiss K, Ferber A, Travali S, Poreu P, Phillips PD, Baserga R (1991) The protooncogene c-myb increases the expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor messenger RNAs by a transcriptional mechanism. Cancer Res 51: 5997-6000
161. Reiss M and Barcellos-Hoff MH (1997) Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45: 81-95
162. Richards RG, DiAugustine RP, Petrusz P, Clark GC and Sebastian J (1996) Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc Natl Acad Sci USA 93: 12002-12007
163. Robertson JF (1996) Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73: 5-12
164. Robertson JF, Williams MR, Todd J, Nicholson RI, Morgan DA and Blamey RW (1980) Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25: 469-475
165. Robertson JF, Bates K, Pearson D, Blamey RW and Nicholson RI (1992) Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 65: 727-730
166. Rochefort H (1995) Oestrogen-and anti-oestrogen-regulated genes in human breast cancer. Ciba Found Symp 191: 254-265
167. Ross JS and Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428
168. Rubino D, Driggers P, Arbit D, Kemp L, Miller B, Coso O, Pagliai K, Gray K, Gutkind S and Segars J (1998) Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action. Oncogene 16, 2513-2526
169. Sala A and Calabretta B (1992) Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. Proc Natl Acad Sci USA 89: 10415-10419
170. Salomon DS, Kim N, Saeki T and Ciardiello F (1990) Transforming growth factor-alpha: an oncodevelopmental growth factor. Cancer Cells 2: 389-397
171. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL and Lee DC (1990) Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61: 1121-1135
172. Santoni-Rugiu E, Jensen MR and Thorgeirsson SS (1998) Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha Cancer Res 58: 123-134
173. Seery LT, Gee JMW, Dewhurst OL and Nicholson RI. Molecular mechanisms of antioestrogen action. In: Handbook of Experimental Pharmacology, Vol 35 (in press)
174. Seery, LT, Knowlden JM, Gee JMW, Robertson JFR, Kenny FS, Ellis IO and Nicholson RI (1999) BRAC1 expression levels predict distant metastasis of sporadic breast cancer. Int J Cancer (in press)
175. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V and Kitchen P (1993) Clinical significance of HER 2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11: 1936-1942
176. Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J and Nicholson RI (1994a) Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 69: 1032-1037
177. Sharma AK, Horgan K, McClelland RA, Douglas-Jones AG, Van Agthoven T, Dorssers LC and Nicholson RI (1994b) A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines. Histochem J 26: 306-310
178. Sharma H and Narayanan R (1996) The NF-kappaB transcription factor in oncogenesis. Anticancer Res 16: 589-596
179. Sivaraman VS, Wang H, Nuovo GJ and Malbon CC (1997) Hyperexpression of mitogen activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483
180. Smith CL, Conncely OM and O'Malley BW (1993) Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc Natl Acad Sci USA 90: 6120-6124
181. Smith CL, Onate SA, Tsai MJ and O'Malley BW (1996) CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 93: 8884-8888
182. Smith CL, Nawaz Z and O'Malley BW (1997) Coactivator and compressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11: 657-666
183. Sonenberg N and Gingras AC (1998) The mRNA 5′ cup-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 10: 268-275
184. Sorrells DL, Black DR, Meschonat C, Rhoads R, De Benedetti A, Gao M, Williams BJ and Li BD (1998) Detection of eIF4E gene amplification in breast cancer by competitive PCR. Ann Surg Oncol 5: 232-237
185. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960
186. Spillman MA and Bowcock AM (1996) BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 13: 1639-1645
187. Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR and Frail DE (1998) A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 273: 27645-27653
188. Sun G, Porter W and Safe S (1998) Estrogen-induced retinoic acid receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complex. Mol Endocrinol 12: 882-890
189. Sutherland RL, Hamilton JA, Sweeney KJ, Watts CK and Musgrove EA (1995) Expression and regulation of cyclin genes in breast cancer. Acta Oncol 34: 651-656
190. Thompson AM, Kerr DJ and Steel CM (1991) Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer 63: 609-614
191. Thompson MA, Rosenthal MA, Ellis SL, Friend AJ, Zorbas MI, Whitehead RH and Ramsay RG (1998) c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression. Cancer Res 58: 5168-5175
192. Tiniakos DG, Scott LE, Corbett IP, Piggott NH and Horne CH (1994) Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4. J Pathol 172: 19-26
193. Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet JC, Powles TJ and Coombes RC (1988) Growth factor expression in normal, benign, and malignant breast tissue. Br Med j (Clin Res Ed) 296: 1621-1624
194. Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P, Avruch J and Rapp UR (1994) Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J Biol Chem 269: 7030-7035
195. Trowbridge JM, Rogatsky I and Garabedian MJ (1997) Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci USA 94: 10132-10137
196. Tzahar E, Waterman M, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287
197. Tzahar E and Yarden Y (1998) The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377: M25-M37
198. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW and McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8: 21-30
199. Umekita Y, Enokizono N, Sagara Y, Kuriwaki K, Takasaki T, Yoshida A and Yoshida H (1992) Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade mitotic index and nodal status. Virchows Arch A Pathol Anat Histopathol 420: 345-351
200. Van Roy F, Marcel M, Vleminckx K, Beyaert R, Fiers W, Devleeschouwer N, Muquardt C, Legros N, Bracke M and Leclercq G (1990) Hormone sensitivity in vitro and in vivo of v-ras-transfected MCF-7 cell derivatives. Int J Cancer 46: 522-532
201. Vladusic EA, Hornby AE, Guerra-Vladusic FK and Lupu R (1998) Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res 58: 210-214
202. Walker KJ, Price-Thomas JM, Candlish W and Nicholson RI (1991) Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 64: 764-768
203. Walker KJ, McClelland RA, Candlish W, Blamey RW and Nicholson RI (1992) Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur J Cancer 28: 34-37
204. Walker RA and Dearing SJ (1992) Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 28: 641-644
205. Walker RA, Jones JL, Chappell S, Walsh T and Shaw JA (1997) Molecular pathology of breast cancer and its application to clinical management. Cancer Metastas Rev 16: 5-27
206. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W and Ullrich A (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275
207. Wang C, Thor AD, Moore DH 2nd, Zhao Y, Kerschmann R, Stern R, Watson PH and Turley EA (1998) The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 4: 567-576
208. Wang Q, Maloof P, Wang H, Fenig E, Stein D, Nichols G, Denny TN, Yahalom J and Wieder R (1998) Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Exp Cell Res 238: 177-187
209. Wasylyk B, Hagman J and Gutierrez-Hartmann A (1998) Ets transcription factors: nuclear effectors of the Ras-MAP kinase signaling pathway. Trends Biochem Sci 23: 213-216
210. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A and Muramatsu M (1997) Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 236: 140-145
211. Watson DM, Elton RA, Jack WJ, Dixon JM, Chetty U and Miller WR (1991) The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat 17: 161-169
212. Webb P, Lopez GN, Uht RM and Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9: 443-456
213. Weisberg E, Sattler M, Ewaniuk DS and Salgia R (1997) Role of focal adhesion proteins in signal transduction and oncogenesis. Crit Rev Oncog 8: 343-358
214. Werner H and Le Roith D (1997) The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 8: 71-92
215. Westley BR, Clayton SJ, Daws MR, Molloy CA and May FE (1998) Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation. Biochem Soc Symp 63: 35-44
216. Whitmarsh AJ and Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74: 589-607
217. Wilcken NRC, Prall OWJ, Musgrove EA and Sutherland RL (1997) Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3: 849-854
218. Williams MR, Todd JH, Nicholson RI, Elston CW, Blamey RW and Griffiths K (1986) Survival patterns in hormone treated advanced breast cancer. Br J Surg 73: 752-755
219. Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE and Westley BR (1993) Type IIGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 29A: 2256-2264
220. Wosikowski K, Eppenberger U, Kung W, Nagamine Y and Mueller H (1992) c-fos, c-jun and c-myc expressions are not growth rate limiting for the human MCF-7 breast cancer cells. Biochem Biophys Res Commun 188: 1067-1076
221. Xie W, Duan R and Safe S (1999) Estrogen induces adenosine deaminase gene expression in MCF-7 human breast cancer cells: role of estrogen receptor-Sp1 interactions. Endocrinology 140: 219-227
222. Yee D (1998) The insulin-like growth factors and breast cancer - revisited. Breast Cancer Res Treat 47: 197-199
223. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R and Michalides RJ (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415
224. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ and Bernards R (1998) Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12: 3488-3498